Lantern Pharma Inc SEC Filings

Lantern Pharma reported first quarter 2026 results showing tighter cost control while advancing its oncology and AI platforms. Research and development expenses fell to approximately $1.7 million, a 47% year-over-year reduction, and net loss narrowed to about $3.3 million, down 27%, or $0.30 per share.

Cash, cash equivalents, and marketable securities were about $6.3 million as of March 31, 2026, and a registered direct offering on May 14, 2026 added roughly $4.4 million in gross proceeds, which the company believes will fund operations into the middle of the first quarter of 2027.

Operationally, Lantern advanced its LP-300 HARMONIC trial with a successful FDA Type C meeting, obtained FDA IND clearance for Starlight Therapeutics’ pediatric CNS cancer trial, launched its multi-agentic AI co-scientist platform withZeta.ai commercially, expanded the predictBBB.ai platform, and outlined plans to separate withZeta.ai into an independent AI-focused entity.

Lantern Pharma reported a Q1 2026 net loss of $3.33 million, narrower than the $4.54 million loss a year earlier, as research and development spending fell to $1.72 million from $3.26 million. General and administrative costs rose modestly to $1.68 million.

Cash, cash equivalents and marketable securities totaled about $6.3 million as of March 31, 2026, with working capital of roughly $3.28 million. The company discloses “substantial doubt” about its ability to continue as a going concern without significant additional funding.

After quarter-end, Lantern raised gross proceeds of approximately $4.4 million through a registered direct equity offering and concurrent private warrants, and now estimates its liquidity will fund operations until around the middle of the first quarter of 2027. Lantern also plans to spin out its withZeta.ai AI platform into an independent, potentially publicly listed entity to pursue dedicated funding separate from its core oncology drug development programs.

Lantern Pharma Inc. entered into a registered direct offering and concurrent private placement raising approximately $4.4 million in gross proceeds. The company sold 1,454,175 common shares at $2.06 per share and issued pre-funded warrants for up to 681,748 shares at $2.0599 each, plus unregistered warrants to purchase up to 2,135,923 shares at an exercise price of $2.27 per share.

The warrants are exercisable starting six months after issuance and expire five years after first exercise, with exercise blocked above a 4.99% or 9.99% ownership cap. Lantern plans to use net proceeds for working capital and general corporate purposes. The company also outlined plans to separate its withZeta.ai AI platform and related assets into an independent entity that may seek its own stock exchange listing and give these investors rights to participate in up to 30% of certain future financings. Lantern agreed not to enter most variable-price financings for two years and temporarily suspended sales under its existing at-the-market program until a new prospectus supplement is filed.

Lantern Pharma Inc. director Lee Troy Schalop reported buying company securities. He acquired 48,544 shares of common stock at $2.06 per share in an open-market purchase, resulting in direct ownership of 48,544 shares after the transaction.

On the same date, he also acquired common stock purchase warrants covering 48,544 underlying shares, with a conversion or exercise price of $2.27 per share and an expiration date of November 13, 2031. According to the disclosure, these warrants were obtained in an offering of securities that closed on May 14, 2026 and will be exercisable starting on November 14, 2026.

Lantern Pharma Inc. director Jeffrey D. Keyser reported buying common stock and warrants. He acquired 48,544 shares of common stock in an open-market purchase at $2.06 per share, bringing his direct holdings to 94,303 shares. He also bought 48,544 common stock purchase warrants with an exercise price of $2.27 per share, each for 48,544 underlying shares of common stock. The securities were acquired in the company’s offering of securities that closed on May 14, 2026, and the warrants are exercisable starting November 14, 2026 and expire on November 13, 2031.

Lantern Pharma Inc. is offering 1,454,175 shares of common stock at $2.06 per share. The offering also includes pre-funded warrants to purchase up to 681,748 shares (exercise price $0.0001) available to purchasers who would otherwise exceed 4.99% (or elect 9.99%) ownership limits.

In a concurrent private placement, Lantern is issuing purchase warrants to buy up to 2,135,923 shares at an exercise price of $2.27 (not registered here). Gross proceeds from the registered component are $4,399,933.20 and estimated net proceeds to Lantern, before expenses, are approximately $4.09 million; Lantern estimates net proceeds after fees and expenses of approximately $3.94 million for use as working capital and general corporate purposes.

Lantern Pharma Inc. filed Amendment No. 1 to its Form 10-K for the year ended December 31, 2025 to replace Part III with updated disclosures on directors, executive compensation, ownership, related-party dealings and auditor fees. The amendment does not change previously reported financial statements.

The filing details 2025 pay for key executives, including total compensation of $763,750 for CEO Panna Sharma and $585,580 for CFO David Margrave, and describes employment terms and bonuses. It also explains a 2025 stock option repricing approved by stockholders and summarizes equity plan usage and major shareholders.

Lantern Pharma Inc. received an updated ownership report from a group of Bios and Cavu investment entities in Amendment No. 6 to a beneficial ownership filing. The group, including Bios Equity Partners, Bios Equity Partners II, Cavu Management, Cavu Advisors and related funds, reports aggregate beneficial ownership of 834,752 shares of common stock, equal to 7.4% of the outstanding shares.

Their shared voting and dispositive power is held through several limited partnerships such as Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT. Percentages are calculated using 11,254,697 shares outstanding as reported in Lantern Pharma’s Form 10‑Q filed on March 16, 2026.

Lantern Pharma Inc. furnished an investor presentation after using it in a live demonstration of withZeta.ai, the company’s multi-agentic AI co-scientist platform for rare cancer drug discovery, development, and clinical trial design. The session covered the platform’s capabilities, commercial architecture, rare cancer market opportunity, competitive positioning, and the company’s near-term revenue strategy and growth roadmap for withZeta.ai.

The presentation is provided as Exhibit 99.1 and a replay of the demonstration is available via an online link. Lantern highlights that the materials contain forward-looking statements about withZeta.ai’s potential advantages, development timelines, market opportunity, and planned use of AI, machine learning, and genomic data, and directs readers to existing risk factors in its latest Annual Report on Form 10-K.